Intra-Cellular Therapies, Inc.

ITCI

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 15, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Lumateperone high dose	Phase 3	Irritability Associated With Autism Spectrum Disorder	-
ITI-007	Phase 3	Schizophrenia	-
ITI-007 (Lumateperone)	Phase 3	Bipolar Depression	-
Placebos	Phase 3	Bipolar Depression	-
Lumateperone	Phase 3	Major Depressive Disorder	-
Lumateperone low dose	Phase 3	Irritability Associated With Autism Spectrum Disorder	-
Lumateperone 42 mg	Phase 3	Schizophrenia	-
Lumateperone (ITI-007)	Phase 3	Bipolar Depression	-
Placebo	Phase 2	Psychosis Associated With Alzheimer's Disease	-
ITI-1284 20 mg	Phase 2	Generalized Anxiety Disorder	-
ITI-214	Phase 2	Heart Failure, Systolic	-
ITI-1284	Phase 2	Agitation Associated With Alzheimer's Dementia	-
Lenrispodun	Phase 2	Parkinson Disease	-
ITI-1284 10 mg	Phase 2	Generalized Anxiety Disorder	-
Risperidone	Phase 2	Schizophrenia	-

Catalyst Timeline

6 upcoming, 0 past

⭐Phase 3Next

Placebo Phase 3 Results Expected

March 2026~Placebo

Primary completion for Placebo trial (NCT06462586) in Bipolar Disorder, Manic

Source

⭐Phase 3

Lumateperone Phase 3 Results Expected

March 2026~Lumateperone

Primary completion for Lumateperone trial (NCT06462586) in Bipolar Disorder, Manic

Source

⭐Phase 3

Lumateperone Phase 3 Results Expected

May 2026~Lumateperone

Primary completion for Lumateperone trial (NCT06462612) in Bipolar Disorder, Manic

Source

⭐Phase 3

Placebo Phase 3 Results Expected

May 2026~Placebo

Primary completion for Placebo trial (NCT06462612) in Bipolar Disorder, Manic

Source

⭐Phase 3

Lumateperone Phase 3 Results Expected

September 2026~Lumateperone

Primary completion for Lumateperone trial (NCT05850689) in Major Depressive Disorder

Source

⭐Phase 3

Placebo Phase 3 Results Expected

September 2026~Placebo

Primary completion for Placebo trial (NCT05850689) in Major Depressive Disorder

Source

Regulatory Approvals

ITCI News

Intra-Cellular Therapies, Inc.

ITCI

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 15, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Lumateperone high dose	Phase 3	Irritability Associated With Autism Spectrum Disorder	-
ITI-007	Phase 3	Schizophrenia	-
ITI-007 (Lumateperone)	Phase 3	Bipolar Depression	-
Placebos	Phase 3	Bipolar Depression	-
Lumateperone	Phase 3	Major Depressive Disorder	-
Lumateperone low dose	Phase 3	Irritability Associated With Autism Spectrum Disorder	-
Lumateperone 42 mg	Phase 3	Schizophrenia	-
Lumateperone (ITI-007)	Phase 3	Bipolar Depression	-
Placebo	Phase 2	Psychosis Associated With Alzheimer's Disease	-
ITI-1284 20 mg	Phase 2	Generalized Anxiety Disorder	-
ITI-214	Phase 2	Heart Failure, Systolic	-
ITI-1284	Phase 2	Agitation Associated With Alzheimer's Dementia	-
Lenrispodun	Phase 2	Parkinson Disease	-
ITI-1284 10 mg	Phase 2	Generalized Anxiety Disorder	-
Risperidone	Phase 2	Schizophrenia	-